Skip to main content
Premium Trial:

Request an Annual Quote

Informax Adopts Shareholder Rights Plan

NEW YORK, June 5 – Bioinformatics company Informax said Tuesday it has adopted a shareholder rights plan designed to stave off an unwanted takeover bid.

The company’s board of directors has declared a dividend that will give shareholders rights to preferred stock. The rights plan has a 15 percent trigger, meaning that the rights can be exercised only if a person or group acquires 15 percent or more of Informax’s common stock.

“The Informax board of directors is taking this action to protect all stockholders of the company,” CEO Alex Titomirov said in a statement. “The rights are designed to provide the board with the flexibility and continued ability to determine the future of Informax and to realize the value of our stockholders' investment in the company."

Informax of Bethesda, Md., follows several other companies that have enacted such plans as genomics shares have continued to show weakness. Over the past few months, Orchid BioSciences, Aclara,  Large Scale Biology, and Illumina  have all adopted such plans amid depressed stock prices.

Informax’ share price, which closed at $7.70 on Tuesday, has recently been climbing back from a 52-week low of $2.85 reached in early May. The share traded at an all-time high of $31.75 in November.

A spokeswoman for Informax said that the rights plan was not implemented in reaction to a takeover bid.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.